Pistachio Intake and Nutrition-Related Outcomes in Individuals on GLP-1 Therapy
NCT07244445 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 108
Last updated 2026-02-20
Summary
In this study will look at how eating pistachios every day might affect participants weight, how healthy their diet is, and how they feel when eating. Investigators want to see if adding pistachios to meals for 12 weeks helps participants feel fuller, have more energy, and improve body composition. The study will include adults who have been taking GLP-1 medicines like semaglutide or tirzepatide for at least three months. Investigators also want to see if eating pistachios improves overall diet quality and health markers like tiredness and certain levels in blood.
Conditions
- Dietary Change
- Obesity & Overweight
- Food Acceptance
Interventions
- DIETARY_SUPPLEMENT
-
Pistachios
Participants will eat 2 ounces, or about 53 grams, of dry-roasted, unsalted pistachios each day along with their regular diet
- PROCEDURE
-
Dual-energy X-ray absorptiometry (DEXA) scans
DEXA scans will be used to measure body fat
Sponsors & Collaborators
-
Ian J. Neeland, MD
lead OTHER
Principal Investigators
-
Ian Neeland, MD · University Hospitals Cleveland Medical Center
-
Abigail Raffner, MD · University Hospitals Cleveland Medical Center
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2026-01-29
- Primary Completion
- 2027-12-31
- Completion
- 2027-12-31
Countries
- United States
More Related Trials
-
Ziprasidone Pharmacokinetics Using a Reduced Food Effect Formulation Compared to Pharmacokinetics From Commercial Capsules
NCT00821444 ·Status: COMPLETED ·Phase: PHASE1
-
Chromium Piccolinate in the Prevention of Weight Gain Induced by Serotonergic Medications Initiated on Psychiatric Inpatient Units.
NCT00759993 ·Status: TERMINATED ·Phase: PHASE2
-
Treatment of Antipsychotic-associated Obesity With a GLP-1 Analogue
NCT01794429 ·Status: COMPLETED ·Phase: PHASE3
-
Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?
NCT04892199 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
The Effect of PinnoThin on Satiety and Food Intake
NCT01034605 ·Status: COMPLETED ·Phase: NA
-
EXOMIND (BTL-699-2) for the Improvement in Willpower & Food Cravings
NCT07056036 ·Status: COMPLETED ·Phase: NA
-
Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders
NCT03943537 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of LDX on Cognitive Processes and Appetite
NCT04181957 ·Status: TERMINATED ·Phase: NA
-
Glucagon-like Peptide 1 (GLP1) Receptor Agonists and Mental Health
NCT05492305 ·Status: UNKNOWN
-
Do Antipsychotics Block Insulin Action in the Brain: is it a Class Effect?
NCT07109245 ·Status: RECRUITING ·Phase: PHASE4
-
Pioglitazone in Patients With Mood Disorders
NCT01559857 ·Status: COMPLETED ·Phase: PHASE4
-
PREDnisolone-induced Beta-cell Dysfunction Prevented by EXenatide
NCT00744224 ·Status: COMPLETED ·Phase: NA
-
Alleviating the Metabolic Side Effects of Antipsychotic Medications
NCT01567124 ·Status: WITHDRAWN ·Phase: PHASE4
-
An Insulin Sensitivity Study in Healthy Subjects
NCT02922426 ·Status: COMPLETED ·Phase: PHASE1
-
Bromocriptine and Insulin Sensitivity
NCT02428946 ·Status: COMPLETED ·Phase: NA
-
One-Year Trial Of Oral Ziprasidone In Patients With Metabolic Syndrome
NCT00748566 ·Status: TERMINATED ·Phase: PHASE4
-
Examination of Bromocriptine on Homeostatic and Hedonic Mechanisms of Food Intake in Individuals at High Risk for T2DM
NCT05405244 ·Status: COMPLETED ·Phase: PHASE3
-
The Effect of Dulaglutide as an Adjuvant Therapy on Cognitive Function in Bipolar Disorder Patients With Obesity
NCT06331286 ·Status: UNKNOWN ·Phase: NA
-
Strategies to Reduce Antipsychotic-Associated Weight Gain in Youth
NCT00617240 ·Status: COMPLETED ·Phase: PHASE2
-
Pfizer/IVGTT/Ziprasidone/Olanzapine
NCT00205725 ·Status: COMPLETED ·Phase: NA
-
Effect of Short Term Atypical Antipsychotic Administration Compared to Placebo on Hepatic Insulin Extraction
NCT02447835 ·Status: COMPLETED ·Phase: PHASE1
-
Tirzepatide for the Treatment of Cannabis Use Disorder
NCT07265752 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Glucose and Lipid Metabolism on Antipsychotic Medication
NCT00515723 ·Status: COMPLETED ·Phase: NA
-
Lifestyle Intervention for Diabetes and Weight Management in Psychosis
NCT01828931 ·Status: COMPLETED ·Phase: NA
-
Effect of RDX-002 on Postprandial Triglycerides in Subjects Treated With Olanzapine
NCT05857566 ·Status: COMPLETED ·Phase: PHASE1